Human UDP-Glucuronosyltransferase (UGT) 2B10: Validation of Cotinine as a Selective Probe Substrate, Inhibition by UGT Enzyme-Selective Inhibitors and Antidepressant and Antipsychotic Drugs, and Structural Determinants of Enzyme Inhibition

Attarat Pattanawongska, Pramod C. Nair, Andrew Rowland, and John O. Miners

Department of Clinical Pharmacology (A.P., P.C.N., A.R., J.O.M.) and Flinders Centre for Innovation in Cancer (A.R., P.C.N., J.O.M.), Flinders University School of Medicine, Adelaide, Australia

Received November 2, 2015; accepted December 14, 2015

ABSTRACT

Although there is evidence for an important role of UGT2B10 in the N-glucuronidation of drugs and other xenobiotics, the inhibitor selectivity of this enzyme is poorly understood. This study sought primarily to characterize the inhibition selectivity of UGT2B10 by UDP-glucuronosyltransferase (UGT) enzyme-selective inhibitors used for reaction phenotyping, and 34 antidepressant and antipsychotic drugs that contain an amine functional group. Initial studies demonstrated that cotinine is a highly selective substrate of human liver microsomal UGT2B10. The kinetics of cotinine N-glucuronidation by recombinant UGT and human liver microsomes (± bovine serum albumin) were consistent with the involvement of a single enzyme. Of the UGT enzyme-selective inhibitors employed for reaction phenotyping, only the UGT2B4/7 inhibitor fluconazole reduced recombinant UGT2B10 activity to an appreciable extent. The majority of antidepressant and antipsychotic drugs screened for effects on UGT2B10 inhibited enzyme activity with IC50 values <100 μM. The most potent inhibition was observed with the tricyclic antidepressants amitriptyline and doxepin and the tetracyclic antidepressant mianserin, and the structurally related compounds desloratadine and loratadine. Molecular modeling using a ligand-based approach indicated that hydrophobic and charge interactions are involved in inhibitor binding, whereas spatial features influence the potency of UGT2B10 inhibition. Respective mean Kd (± S.D.) values for amitriptyline, doxepin, and mianserin inhibition of human liver microsomal UGT2B10 were 0.61 ± 0.05, 0.95 ± 0.18, and 0.43 ± 0.01 μM. In vitro–in vivo extrapolation indicates that these drugs may perpetrate inhibitory drug-drug interactions when coadministered with compounds that are cleared predominantly by UGT2B10.

Introduction

Enzymes of the UDP-glucuronosyltransferase (UGT) superfamily catalyze the covalent linkage (conjugation) of glucuronic acid, which is derived from the cofactor UDP-glucuronic acid (UDP-GlcUA), to a typically lipophilic substrate containing a nucleophilic acceptor functional group. Functional groups that are glucuronidated include hydroxyl (aliphatic and phenolic), carboxylic acids, amines (primary, secondary, tertiary, and aromatic), and thiols. Consistent with the ability of UGTs to metabolize compounds containing these commonly occurring functional groups, glucuronidation serves as an elimination and detoxification mechanism for drugs from almost all therapeutic classes, non-drug xenobiotics, endogenous compounds, and the products of oxidative metabolism (Miners and Mackenzie, 1991; Miners et al., 2004; Kiang et al., 2005). Twenty-two human UGT proteins have been identified to date (Mackenzie et al., 2005). Nineteen of these, classified in the UGT 1A, 2A, and 2B subfamilies, primarily use UDP-GlcUA as cofactor.

A.P. is the recipient of a Flinders University postdoctoral fellowship.

dx.doi.org/10.1124/dmd.115.068213.

This article has supplemental material available at dmd.aspetjournals.org.

Available evidence indicates that the individual UGT enzymes exhibit distinct but sometimes overlapping substrate and inhibitor selectivities (Miners et al., 2004, 2010a; Rowland et al., 2013). However, data are lacking for several UGTs, especially with respect to inhibitor profiles. UGT2B10 was cloned initially in this laboratory and demonstrated to lack activity toward hydroxylated xenobiotics and steroids (Jin et al., 1993). The inability of UGT2B10 to catalyze the O-glucuronidation of these compounds was subsequently shown to arise from substitution of the near conserved His, present in the N terminus putative substrate binding domain of all UGT family 1 and 2 enzymes except UGT1A4 and UGT2B10, with Leu (Kerdpin et al., 2009). Substitution of Leu34 of UGT2B10 with His, which functions as the catalytic base in O-glucuronidation reactions, generated an enzyme that metabolized the phenols 4-methylumbelliferone (4MU) and 1-naphthol.

Although initially considered an orphan enzyme, more recent studies have shown that UGT2B10, like UGT1A4, catalyzes the N-glucuronidation of a number of xenobiotics that incorporate an aliphatic tertiary amine or aromatic N-heterocyclic group (Kaivosaaari et al., 2011). Known substrates are nicotine and its oxidation product cotinine (Chen et al., 2007; Kaivosaaari et al., 2007); desloratadine (Kazmi et al., 2015a); metsudomimide (Kaivosaaari et al., 2008); the tricyclic antidepressants amitriptyline, doxepin, and mianserin inhibition of human liver microsomal UGT2B10 were 0.61 ± 0.05, 0.95 ± 0.18, and 0.43 ± 0.01 μM. In vitro–in vivo extrapolation indicates that these drugs may perpetrate inhibitory drug-drug interactions when coadministered with compounds that are cleared predominantly by UGT2B10.
(TCAs) amitriptyline, clomipramine, imipramine, and trimipramine (Chen et al., 2007; Zhou et al., 2010; Kato et al., 2013); several tobacco-specific nitrosamines (Chen et al., 2008); RO5263397 (Fowler et al., 2015); and miscellaneous drugs that include diphenhydramine, ketocanozole, ketotifen, midazolam, olanzapine, pizotifen, and tamoxifen (Erickson-Ridout et al., 2011; Kato et al., 2013). Consistent with the known selectivity of UGT1A4 for N-glucuronidation (Kubota et al., 2007), most, if not all, UGT2B10 substrates are additionally glucuronidated by UGT1A4 and biphasic kinetics are frequently observed when human liver microsomes (HLM) are used as the enzyme source (Kaivosaaari et al., 2011; Kato et al., 2013). However, available evidence indicates that UGT2B10 is the high-affinity enzyme involved in most reactions.

The UGT2B10 substrates desloratadine and nicotine further act as inhibitors of this enzyme. In particular, desloratadine has been reported to be a relatively selective and potent competitive inhibitor of UGT2B10, with a \( K_i \) of 1.3 \( \mu \)M (Kazmi et al., 2015b). Nicotine has also been employed as an inhibitor of UGT2B10 in vitro, although the UGT enzyme inhibition selectivity of this compound is incompletely characterized (Zhou et al., 2010). A large number of clinically used drugs contain an aliphatic amine or aromatic N-heterocyclic group. Notable in this regard are antidepressants [TCAs, selective serotonin reuptake inhibitors (SSRIs), serotonin and noradrenaline reuptake inhibitors (SNRIs), tetracyclic antidepressants, and monoamine oxidase inhibitors (MAOIs)] and antipsychotics (both typical and atypical). Indeed, the majority of drugs in these classes are either tertiary or secondary aliphatic amines. Despite their widespread clinical use, however, the potential inhibition of UGT2B10 by these compounds has not been explored in a systematic manner. Furthermore, knowledge of the effects of UGT enzyme-selective inhibitors employed for reaction phenotyping in vitro on UGT2B10 activity is similarly lacking (Miners et al., 2010a).

Thus, the aims of the present study were to confirm the UGT enzyme selectivity of cotinine as a UGT2B10 substrate and desloratadine and nicotine as UGT2B10 inhibitors; investigate the potential inhibition of UGT2B10 by currently used UGT enzyme-selective inhibitors employed for reaction phenotyping; and characterize the inhibition of UGT2B10 by 34 amine (primary, secondary, and tertiary) containing antidepressants and antipsychotics from various classes (TCAs, SSRIs, SNRIs, MAOIs, and typical and atypical antipsychotics). Data generated from these studies were employed to identify the structural features of compounds required for potent inhibition of UGT2B10 and to provide insights into potential drug-drug interactions (DDIs) arising from inhibition of this enzyme.

Materials and Methods

Materials

Alamethicin (from Trichoderma viride), amitriptyline hydrochloride (HCl), aripiprazole, bovine serum albumin (BSA; essentially fatty acid free), chlorpromazine HCl, clomipramine HCl, clozapine, codeine, S-(-)-cotinine, desipramine HCl, desvenlafaxine HCl, dicyclofenac (sodium salt), doxepin HCl, fluphenazine HCl, fluvoxamine maleate, hecogenin, hecogenin HCl, 4MU, 4-methylumbelliferone glucuronide, mirtazapine, S-(-)-nicotine, niflumic acid, norclomipramine HCl, nortriptyline HCl, paroxetine, phenylbutazone, propriptene HCl, selegiline HCl, thioridazine HCl, tranylcyprone HCl, trimipramine HCl, and UDF-GluCA (trisodium salt) were purchased from Sigma-Aldrich (Sydney, Australia); codeine 6-O-glucuronide, cotinine N-\( \beta \)-glucuronide, citalopram hydrobromide, desmethylnortriptyline HCl from Roche (Basel, Switzerland); desmethylnortriptyline HCl from Ciba-Geigy (Basel, Switzerland); diphenhydramine, doxepin HCl, fluphenazine HCl, clomipramine HCl, clozapine, codeine, S-(-)-cotinine, desipramine HCl, aripiprazole, bovine serum albumin (BSA; essentially fatty acid free), chlorpromazine HCl, clomipramine HCl, clozapine, codeine, S-(-)-cotinine, desipramine HCl, dicyclofenac (sodium salt), doxepin HCl, fluphenazine HCl, fluvoxamine maleate, hecogenin, hecogenin HCl, 4MU, 4-methylumbelliferone glucuronide, mirtazapine, S-(-)-nicotine, niflumic acid, norclomipramine HCl, nortriptyline HCl, paroxetine, phenylbutazone, propriptene HCl, selegiline HCl, thioridazine HCl, tranylcyprone HCl, trimipramine HCl, and UDF-GluCA (trisodium salt) were purchased from Sigma-Aldrich (Sydney, Australia); dexamethasone, dexamethasone hydrochloride, and dexamethasone phosphate from Sigma-Aldrich (Sydney, Australia); dexamethasone N-glucuronide, citalopram hydrobromide, desmethylnortriptyline HCl from Roche (Basel, Switzerland); fluconazole from Pfizer Australia (Sydney, Australia); lamotrigine and lamotrigine N2-glucuronide from the Wellcome Research Laboratories (Beckenham, UK); ketonazole and itraconazole from Janssen Research Foundation (New York, NY); mianserin HCl from Akzo Pharmaceutical Division (Amherst, The Netherlands); and loxapine from Alexza Pharmaceuticals (Mountain View, CA). Suprosomes expressing UGT2B4, UGT2B7, UGT2B10, UGT2B15, and UGT2B17 and pooled HLM (150 donor pool; equal number of males and females) were purchased from BD Biosciences (San Jose, CA). Rapid equilibrium dialysis (RED) inserts and base plates were purchased from Thermo Scientific (Rockford, IL). Solvents and other reagents used were of analytical reagent grade.

Methods

HLM and Recombinant Human UGTs

Approval for the use of human liver tissue for in vitro drug metabolism studies was obtained from the Southern Adelaide Clinical Research Ethics Committee. HLM were activated by preincubation with the pore-forming agent alamethicin (50 \( \mu \)g/ml microsomal protein) prior to use in incubations according to Boose and Miners (2002). Human UGT 1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B10, 2B15, and 2B17. Incubations (100 \( \mu \)l total volume) contained cotinine (0.25, 1, and 5 mM), Supersome or HEK293 lysate protein (1 mg/ml), 0.1 M phosphate buffer (pH 7.4), and 4 mM MgCl\(_2\). The incubation mixtures were preincubated at 37°C for 5 minutes, and then reactions were initiated by the addition of 5 mM UDP-GlcUA. Incubations were performed at 37°C for 120 minutes, after which time reactions were terminated by the addition of 11.6 M HClO\(_4\), (1 \( \mu \)l). Samples were cooled on ice for 10 minutes and then centrifuged at 5000 \( \times \)g, 4°C, for 10 minutes. An aliquot was injected onto the high-performance liquid chromatography (HPLC) column (see below). For the kinetic characterization of cotinine N-glucuronidation by recombinant UGT2B10 and HLM, incubations were conducted as described above for recombinant UGTs and contained either UGT2B10-expressing Supersomes (1 mg/ml) or HLM (0.5 mg/ml). The kinetics of cotinine N-glucuronidation were characterized in the absence and presence of BSA (1% w/v). Incubations containing BSA were terminated by the addition of 3 \( \mu \)l 11.6 M HClO\(_4\).

Quantification of Cotinine N-Glucuronide Formation

Cotinine N-glucuronide formation was measured using an Agilent 1200 series HPLC system (Agilent Technologies, Sydney, Australia) fitted with a Zorbax Eclipse XBD-C8, 4.6 \( \times \) 150 mm, 5 \( \mu \)m (Agilent Technologies). Cotinine N-glucuronide was eluted by isocratic elution with a 90:6 mixture of mobile phases A (4 mM l-octanol-sulfonic acid adjusted to pH 2.7 with 11.6 M HClO\(_4\)) and B (aconitrite) at a flow rate of 1 ml/min. Column eluent was monitored at a wavelength of 254 nm. The retention times of cotinine N-glucuronide and cotinine were 7 and 43 minutes, respectively. Cotinine N-glucuronide was quantified by reference to a calibration curve prepared using an authentic standard. Calibration curve concentration ranges were 1–5 \( \mu \)M and 1–25 \( \mu \)M with UGT2B10 and HLM as the respective enzyme sources.

Inhibition of Recombinant Human UGT2B10 Activity by Antidepressants, Antipsychotics, and Other Compounds

The inhibition of recombinant human UGT2B10 enzyme activity was determined for 43 compounds (see Results). Effects on UGT2B10 activity were investigated at four inhibitor concentrations (1, 10, 100, and 500 \( \mu \)M), except for fluconazole (1, 2.5, 5, and 10 mM), hecogenin (1, 10, 50, and 100 \( \mu \)M), ketonazole (1, 10, 50, and 100 \( \mu \)M), and niflumic acid (1, 10, 100, and 200 \( \mu \)M). Stock solutions of the antidepressant and antipsychotic drugs available as salts (see Materials and Methods) were prepared in water. Stock solutions of all other inhibitors were prepared in dimethylsulfoxide, with the following exceptions: desloratadine and nicotine stock solutions were prepared in ethanol, whereas hecogenin was dissolved in methanol. The final concentration of solvent present in
incubation mixtures was 1% (v/v). The inhibition studies were performed at a cotinine concentration of 2.8 mM, which corresponds to the apparent $K_m$ for cotinine N-glucuronidation by recombinant UGT2B10 (see Results).

Inhibition of Recombinant Human UGT Enzyme Activities by Desloratadine and Nicotine. In addition to effects on UGT2B10, desloratadine and nicotine (1, 10, 100, and 500 $\mu$M) were screened for inhibition of the UGT1A1 and UGT2B8 subfamily enzymes UGT 1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B15, and 2B17. Effects on all enzymes except UGT1A4 and UGT2B4 were determined using the nonselective substrate 4MU. The 4MU concentration used in incubations corresponded to the published apparent $K_m$ and $V_{max}$ for each enzyme, whereas protein concentrations and incubation time varied for each enzyme, as described by Uchaipichat et al. (2004). The 4MU glucuronide formation was quantified according to Lewis et al. (2007). Inhibition of UGT1A4 by desloratadine and nicotine was assessed with lamotrigine as the probe substrate following the method of Rowland et al. (2006), whereas effects on UGT2B4 activity were determined with codeine as the substrate, as described by Raungrut et al. (2010). Concentrations of lamotrigine and codeine used in the UGT1A4 and UGT2B4 inhibition-screening studies corresponded to the respective $K_m$ values for each substrate/pair: 1.5 mM for lamotrigine/UGT1A4 and 2.0 mM for codeine/UGT2B4. Positive control inhibitors were used in all inhibition screening experiments, as described in Pattanawongsa et al. (2015).

The magnitude of inhibition of each positive control inhibitor (data not shown) was as expected from previous studies in this laboratory (Uchaipichat et al., 2004, 2006a, 2006b; Raungrut et al., 2010; Miners et al., 2011).

Inhibition of Human Liver Microsomal Cotinine N-Glucuronidation by Hecogenin and Desloratadine. The relative contributions of UGT1A4 and UGT2B10 to human liver microsomal cotinine N-glucuronidation were investigated using the selective inhibitors hecogenin (UGT1A4; Uchaipichat et al., 2006a) and desloratadine (Kazmi et al., 2015b and Results). The effects of each inhibitor (10 $\mu$M) were determined at each of four cotinine concentrations (0.25, 1, 3, 6 mM) following the procedure described in Cotinine N-glucuronidation by recombinant UGTs and HLM. The formation of cotinine N-glucuronide in the presence of desloratadine or hecogenin or a combination of both was compared with metabolite production in the absence of the inhibitors.

Kinetic Characterization of Amitriptyline, Doxepin, and Mianserin Inhibition of Human Liver Microsomal Cotinine N-Glucuronidation. The kinetics and mechanism of the inhibition of cotinine N-glucuronidation by amitriptyline, doxepin, and mianserin were characterized with HLM as the enzyme source following the method described above. Experiments to characterize inhibitor constants ($K_i$) employed HLM (0.5 mg/ml) supplemented with BSA (1% w/v). Effects of four added concentrations (1, 2.5, 5, and 10 $\mu$M) of each of amitriptyline, doxepin, and mianserin were characterized at each of the three added cotinine concentrations (1, 2, and 3 mM). Concentrations of each of the inhibitors were corrected for nonspecific binding to HLM and BSA.

Measurement of the Nonspecific Binding of Cotinine to Supersomes, HLM, and BSA, and Amitriptyline, Doxepin, and Mianserin to HLM and BSA. Nonspecific binding experiments were performed using rapid equilibrium dialysis (RED) devices fitted with an 8-kDa molecular weight cutoff cellulose membrane, as described by Pattanawongsa et al. (2015). For the assessment of cotinine binding, the sample chamber was loaded with cotinine (0.1–15 mM) and Supersome protein (1 mg/ml) or HLM (0.5 mg/ml) or BSA (1% w/v), in 0.1 M phosphate buffer (pH 7.4, total volume 100 $\mu$l). The buffer chamber was loaded with 300 $\mu$l 0.1 M phosphate buffer (pH 7.4). Experiments were also performed with buffer-buffer, enzyme-enzyme, and BSA-BSA controls. The RED devices were incubated at 37°C for 5 hours, by which time equilibrium had been achieved. A 30 $\mu$l aliquot was collected from each chamber, and protein was precipitated with 0.5 ml 11.6 M HClO$_4$, or with 0.9 ml 11.6 M HClO$_4$ for samples containing BSA. Samples were cooled on ice for 10 minutes and then centrifuged (5000g) at 4°C for 10 minutes. A 10 $\mu$l aliquot was diluted with 90 $\mu$l 5% acetonitrile in water. Cotinine was analyzed by HPLC following the procedure described for cotinine N-glucuronide, but using 83% mobile phase A and 17% mobile phase B. Under these conditions, the retention time of cotinine was 4.6 minutes.

The binding of amitriptyline, doxepin, and mianserin (2, 5, 10, and 25 $\mu$M) to HLM (0.5 mg/ml) plus BSA (1% w/v) was similarly measured using the RED device. Like cotinine, experiments were performed with buffer-buffer and protein-protein controls. After 8-hour equilibration, a 70 $\mu$l aliquot was taken from each chamber and mixed with four volumes of 4% acetic acid in methanol, which also contained the assay internal standard (Supplemental Table 1). Samples were cooled on ice for 10 minutes, and then centrifuged (5000g) at 4°C for 10 minutes. The supernatant fraction was decanted and evaporated to dryness using a miVac modular concentrator (Genecine, Suffolk, UK). The residue was reconstituted in 50 $\mu$l mobile phase and analyzed by HPLC (see Supplemental Table 1 for conditions).

Molecular Modeling. The three-dimensional coordinates (sdot format) of dataset molecules were obtained from the Pubchem server (https://pubchem.ncbi.nlm.nih.gov/). The molecules were imported into SYBYL (version 2.1, CERTARA, Princeton, NJ) and geometry optimized using the AM1 Hamiltonian (MOPAC). All molecular modeling was performed using SYBYL installed on a Macintosh workstation running on OS X 10.9.5 operating system. The structural overlay of molecules was undertaken using the Sulfex-Sim program (Jain, 2000, 2004), which utilizes the morphologic similarity approach to generate alignments of molecules. Similarity is defined as a Gaussian function of the differences in the molecular surface distances of two molecules at weighted observation points on a uniform grid. The computed surface represents distances to the nearest atomic surface and distances to donor and acceptor surfaces.

Amitriptyline, one of the most potent UGT2B10 inhibitors (see Results), was used as the template for the overlay of dataset molecules. The overlay quality of the dataset molecules was evaluated by measuring the distance between key pharmacophoric features, including the centroid of either of the phenyl rings (present in the tricylic structure of amitriptyline) and the aryl ring (closest) of the dataset molecule observed in the alignment. Moreover, the distances between the side-chain amine N atom of amitriptyline and the dataset molecules (aliphatic or alicyclic) were also estimated. The smaller the distance, the more closely the pharmacophoric features overlay between amitriptyline and the dataset molecule. In addition, for tri- and tetracyclic compounds, the angles between the rings of the tricyclic scaffold were measured by defining a centroid for each ring on the geometry optimized structures. The torsion angles were measured for the bridge (-CH$_2$-X where X= -CH$_2$, -O, or -N) connecting the two aromatic rings of the tricyclic scaffold. For example, in the case of amitriptyline, the torsion angle was measured for the dimethylene (-CH$_2$-CH$_2$-) bridge of the central seven-membered (cycloheptene) ring.

Data Analysis. The Michaelis-Menten equation (eq. 1) was fit to kinetic data for cotinine N-glucuronidation by UGT2B10 and HLM (±1% BSA) using Enzfitter (version 2.0, Biosoft, Cambridge, UK) to obtain values of $K_m$ and $V_{max}$. Inhibitor constants, based on unbound concentrations of amitriptyline, doxepin, and mianserin present in incubations ($K_i$), were determined by fitting the expressions given in eq. 2–4 to experimental data using Enzfitter. Goodness of fit of all expressions was assessed from comparison of the parameter S.E. of fit, coefficient of determination ($r^2$), 95% confidence intervals, and F-statistic.

Equation 1, Michaelis-Menten equation:

$$v = \frac{V_{max} \times [S]}{K_m + [S]}$$

where $v$ is the rate of product formation, $V_{max}$ is maximal velocity, [S] is substrate concentration, and $K_m$ is the Michaelis constant.

Equation 2, competitive inhibition:

$$v = \frac{V_{max} \times [S]}{K_m + [I] + [S]}$$

where [I] is the inhibitor concentration and $K_i$ is the inhibitor constant (for the EI complex).

Equation 3, noncompetitive inhibition:

$$v = \frac{V_{max} \times [S]}{(1 + [I]/K_i)(K_m + [S])}$$

where $K_i$ is the inhibitor constant for the EI and ESI complexes.

Equation 4, mixed (competitive–noncompetitive) inhibition:

$$v = \frac{V_{max} \times [S]}{K_m + [I]/K_i + [S](1 + [I]/K_i')}$$

where $K_i$ and $K_i'$ are the inhibitor constants for the EI and ESI complexes, respectively.
IC50 values were determined according to equation 5:

\[
v_i = v_0 \left[ 1 - \frac{[I]}{[I] + IC_{50}} \right]
\]

where \(v_0\) is the control activity and \(v_i\) is the activity in the presence of the inhibitor (I).

For a drug metabolized by a single enzyme along a single metabolic pathway, the extent of inhibition of the hepatic clearance by a coadministered drug [determined as the ratio of the areas under the plasma drug concentration–time curves (AUC) with and without inhibitor coadministration] may be calculated according to eq. 6, which is valid for competitive and noncompetitive inhibition:

\[
\frac{AUC_i}{AUC} = 1 + \frac{[I]}{K_i}
\]

where \([I]\) is the inhibitor concentration. Optimally, \([I]\) is taken as the hepatic inlet concentration (Miners et al., 2010b), but given the unavailability of key pharmacokinetic parameters (particularly absorption rate constant) for amitriptyline, doxepin, and mianserin, the maximum drug plasma concentration (\(C_{\text{max}}\)) was used as the estimate of \([I]\) in the calculation of the AUC ratio. Amitriptyline (50 mg dose): mean \(C_{\text{max}}\) 0.15 \(\mu\)M (Kakes et al., 2009), fraction unbound in plasma (\(fu\)) 0.065 (Baumann et al., 1986). Assuming linear kinetics, the \(C_{\text{max}}\) expected for a single 150 mg dose of amitriptyline is 0.45 \(\mu\)M. Doxepin (50 mg dose): mean \(C_{\text{max}}\) 0.29 \(\mu\)M (Virtanen et al., 1980), \(fu\) 0.79 (Faulkner et al., 1983). Again, assuming linear kinetics, the \(C_{\text{max}}\) expected for a single 150 mg dose of doxepin is 0.87 \(\mu\)M. Mianserin (60 mg dose): mean \(C_{\text{max}}\) 0.38 \(\mu\)M (Hrdina et al., 1983), \(fu\) 0.055 (Kristensen et al., 1985).

Statistical comparisons of kinetic constants reported in Table 1 were performed using the Mann-Whitney \(U\) test with SPSS version 22 (SPSS, Chicago, IL). \(P\) values \(< 0.05\) were considered significant.

**Results**

**Kinetics of Cotinine N-Glucuronidation.** Cotinine N-glucuronidation by recombinant UGT2B10 and HLM (± BSA, 1% w/v) followed Michaelis-Menten kinetics (Fig. 1). Mean (± S.D.) kinetic constants are given in Table 1. The mean \(K_m\) for human liver microsomal cotinine N-glucuronidation was marginally higher (\(P = 0.06\)) than that for UGT2B10, whereas the \(V_{\text{max}}\) with HLM as the enzyme source was 6.8-fold higher compared with UGT2B10. The activities of numerous UGTs, particularly with HLM as the enzyme source, are known to be increased in the presence of BSA (0.5–2% w/v) due to sequestration of inhibitory membrane long-chain unsaturated fatty acids released during the course of an incubation (Rowland et al., 2007, 2008; Kilford et al., 2009; Manevski et al., 2011; Walsky et al., 2012). Addition of BSA (1% w/v) to incubations of HLM resulted in a 45% reduction in \(K_m\) and a small (11%) but statistically significant increase in \(V_{\text{max}}\). The mean \(Cl_{\text{int}}\), calculated as \(V_{\text{max}}/K_m\), for human liver microsomal cotinine N-glucuronidation derived in the presence of BSA was approximately double that determined in the absence of BSA. Cotinine was shown not to bind (\(fu_{\text{mic}}\) > 0.95) to Supersomes (1 mg/ml), HLM (0.5 mg/ml), or BSA (1% w/v). Thus, correction of \(K_m\) and \(Cl_{\text{int}}\) values for substrate-binding HLM and BSA was not required.

**Confirmation of the UGT2B10 Substrate Selectivity of Cotinine and Inhibitor Selectivity of Desloratadine and Nicotine.** Cotinine N-glucuronidation by UGT 1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9,
1A10, 2B4, 2B7, 2B10, 2B15, and 2B17 was investigated at three substrate concentrations (0.25, 1, and 5 mM) that spanned the $K_m$ values reported in Table 1. Activity was observed only with UGT1A4 and UGT2B10. The respective mean N-glucuronidation rates by UGT2B10 at the three cotinine concentrations were 6.0, 15.4, and 38.0 pmol/min.mg. By contrast, with UGT1A4 as the enzyme source, cotinine N-glucuronidation (2.3 pmol/min.mg) was observed at just the highest substrate concentration.

**Fig. 2.** Inhibition of recombinant human UGT enzymes by nicotine (A) and desloratadine (B). Each bar represents the mean of duplicate measurements (<5% variance). See Materials and Methods for experimental conditions.
Nicotine and desloratadine (1, 10, 100, and 500 μM) were screened for inhibition of UGT 1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B10, 2B15, and 2B17. Over the concentration range investigated, nicotine inhibited only UGT2B10 with an IC₅₀ < 500 μM (Fig. 2A); the mean (± S.E. of parameter fit) IC₅₀ value was 214 ± 2.9 μM. Consistent with the recent report of Kazmi et al. (2015b), desloratadine potently inhibited UGT2B10 (IC₅₀ 3.86 ± 0.05 μM). IC₅₀ values for other hepatically expressed UGT enzymes ranged from 18.9 ± 0.10 μM for UGT2B4 to 271 ± 7.6 μM for UGT1A6 (Fig. 2B; Supplemental Table 2). In general, the inhibition observed in this study for desloratadine (10 μM) is in good agreement to that reported by Kazmi et al. (2015b) for heptatically expressed UGT enzymes, except UGT2B4, which was not investigated by these authors.

Inhibition of Recombinant UGT2B10 by UGT Enzyme-Selective Inhibitors. Effects of putative UGT enzyme-selective inhibitors on recombinant UGT2B10 activity were assessed using cotinine as the substrate probe. The UGT1A4 inhibitor hecgenin (1–100 μM) was without effect on UGT2B10 activity (Table 2), consistent with the observations of Guo et al. (2011) and Kato et al. (2013). Niflumic acid, without effect on UGT2B10 activity (Table 2), consistent with the recombinant UGT2B10 activity were assessed using cotinine as the substrate probe. The UGT1A4 inhibitor hecgenin (1–100 μM) was without effect on UGT2B10 activity (Table 2), consistent with the observations of Guo et al. (2011) and Kato et al. (2013). Niflumic acid, which inhibits UGT1A9 with a Kᵢ of 0.10 μM and UGT1A1 and UGT2B15 with respective Kᵢ values of 18 and 62 μM (Miners et al., 2011), inhibited UGT2B10 with an IC₅₀ of 168 ± 0.14 μM (Table 2). Fluconazole, employed as a selective inhibitor of UGT2B4 and UGT2B7 (Uchaipichat et al., 2006b; Raungrut et al., 2010), inhibited UGT2B10 with an IC₅₀ of 1136 ± 88.4 μM (Table 2), whereas phenylbutazone, which has been reported to be a relatively selective inhibitor of UGT1A subfamily enzyme activities (Uchaipichat et al., 2006a), inhibited UGT2B10 with an IC₅₀ of 220 ± 35.4 μM. The effect of fluconazole on UGT2B10 prompted us to investigate the effects of two other azole antifungal agents, itraconazole and ketoconazole. Whereas itraconazole was without effect on UGT2B10, ketoconazole was a relatively potent inhibitor of this enzyme (IC₅₀ = 11.9 ± 1.7 μM; Table 2).

The Contribution of UGT2B10 to Human Liver Microsomal Cotinine N-Glucuronidation. As shown above, of the heptatically expressed enzymes in the UGT 1A and 2B subfamilies, only UGT1A4 and UGT2B10 glucuronidated cotinine. Inhibition studies with hecgenin and desloratadine were performed to elucidate the relative contributions of these enzymes to human liver microsomal cotinine N-glucuronidation. Effects of desloratadine and hecgenin (both 10 μM), separately and combined, were determined at four cotinine concentrations that spanned the Kᵢ for cotinine N-glucuronidation by HLM (viz. 0.25, 1, 3, and 6 mM). Hecgenin had a negligible effect (<10% inhibition) at all cotinine concentrations (Fig. 3). By contrast, desloratadine, alone and in combination with hecgenin, inhibited human liver microsomal cotinine N-glucuronidation to a near-identical extent (Fig. 3). It should be noted that the extent of cotinine N-glucuronidation observed with 10 μM desloratadine is broadly consistent with IC₅₀ for desloratadine (~4 μM) reported in Table 2. Consistent with competitive inhibition by desloratadine (Kazmi et al., 2015b), greater and lesser inhibition occurred at cotinine concentrations below and above the Kᵢ, respectively. Collectively, the data indicate that cotinine is a selective substrate of human liver microsomal UGT2B10.

Inhibition of Recombinant UGT2B10 by Antidepressant and Antipsychotic Drugs: Modeling and Structure-Activity Relationships. Thirty-four antidepressant drugs (including desmethylimipramine and desmethylnortriptyline, the respective demethylated metabolites of desipramine and nortriptyline) were screened as potential inhibitors of UGT2B10 (Table 2). The most potent inhibition was observed for mianserin, doxepin, and amitriptyline, which have IC₅₀ values in the range 2.2–6.5 μM. IC₅₀ values for the structurally related compounds loratadine and desloratadine were also in this range (Table 2). Twenty-five compounds additionally exhibited moderately potent inhibition (IC₅₀ values 26–94 μM), whereas six were weak (IC₅₀ > 200 μM) or noninhibitors.

Ligand-based approaches were employed to identify the structural features associated with significant inhibition. The majority of significant inhibitors (arbitrarily defined as having an IC₅₀ < 100 μM) are generally tri- or tetracyclic structures with an amine-containing side chain (aliphatic...

### Table 2

<table>
<thead>
<tr>
<th>Classification</th>
<th>Drug</th>
<th>IC₅₀ (μM) ± S.E. of Parameter Fit</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>UGT enzyme-selective inhibitors</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Desloratadine</td>
<td>3.86 ± 0.05</td>
<td></td>
</tr>
<tr>
<td>Fluconazole</td>
<td>1136 ± 88.4</td>
<td></td>
</tr>
<tr>
<td>Hecgenin</td>
<td>NI</td>
<td></td>
</tr>
<tr>
<td>(-)-Nicotine</td>
<td>214 ± 2.86</td>
<td></td>
</tr>
<tr>
<td>Niflumic acid</td>
<td>168 ± 0.14</td>
<td></td>
</tr>
<tr>
<td>Phenylbutazone</td>
<td>220 ± 35.4</td>
<td></td>
</tr>
<tr>
<td>Loratadine (desloratadine precursor)</td>
<td>2.18 ± 0.34</td>
<td></td>
</tr>
<tr>
<td><strong>Azoles</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Itraconazole</td>
<td>NI</td>
<td>11.9 ± 1.6</td>
</tr>
<tr>
<td>Ketoconazole</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Antidepressants</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TCAs</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary amine</td>
<td>Desmethylamitriptyline</td>
<td>43.7 ± 2.08</td>
</tr>
<tr>
<td>Secondary amine</td>
<td>Desmethyliminipramine</td>
<td>36.2 ± 0.40</td>
</tr>
<tr>
<td>Tertiary amine</td>
<td>Amitriptyline</td>
<td>6.45 ± 0.46</td>
</tr>
<tr>
<td>Tertiary amine</td>
<td>Clomipramine</td>
<td>26.0 ± 0.49</td>
</tr>
<tr>
<td>Tertiary amine</td>
<td>Doxepin</td>
<td>3.64 ± 0.16</td>
</tr>
<tr>
<td>Tertiary amine</td>
<td>Imipramine</td>
<td>42.8 ± 1.52</td>
</tr>
<tr>
<td>Tertiary amine</td>
<td>Trimipramine</td>
<td>32.6 ± 1.70</td>
</tr>
<tr>
<td><strong>SSRIs</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary amine</td>
<td>Fluvoxamine</td>
<td>224 ± 6.11</td>
</tr>
<tr>
<td>Secondary amine</td>
<td>Fluoxetine</td>
<td>72.4 ± 15.8</td>
</tr>
<tr>
<td>Tertiary amine</td>
<td>Paroxetine</td>
<td>63.5 ± 4.79</td>
</tr>
<tr>
<td>Tertiary amine</td>
<td>Sertraline</td>
<td>92.7 ± 8.99</td>
</tr>
<tr>
<td><strong>SNRIs</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Secondary amine</td>
<td>Duloxetine</td>
<td>81.2 ± 8.17</td>
</tr>
<tr>
<td>Tertiary amine</td>
<td>Desvenlafaxine</td>
<td>440 ± 16.5</td>
</tr>
<tr>
<td><strong>MAOs</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary amine</td>
<td>Tranylcypromine</td>
<td>NI</td>
</tr>
<tr>
<td>Tertiary amine</td>
<td>Selegiline</td>
<td>67.2 ± 3.60</td>
</tr>
<tr>
<td><strong>Antipsychotics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary amine</td>
<td>Chlorpromazine</td>
<td>79.0 ± 10.7</td>
</tr>
<tr>
<td>Secondary amine</td>
<td>Fluphenazine</td>
<td>53.5 ± 6.54</td>
</tr>
<tr>
<td>Tertiary amine</td>
<td>Haloperidol</td>
<td>NI</td>
</tr>
<tr>
<td><strong>Atypical antipsychotics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary amine</td>
<td>Aripiprazole</td>
<td>55.8 ± 0.80</td>
</tr>
<tr>
<td>Tertiary amine</td>
<td>Clozapine</td>
<td>61.3 ± 1.40</td>
</tr>
<tr>
<td>Tertiary amine</td>
<td>Olanzapine</td>
<td>276 ± 4.49</td>
</tr>
<tr>
<td>Tertiary amine</td>
<td>Quetiapine</td>
<td>43.9 ± 7.65</td>
</tr>
</tbody>
</table>

**NI**, negligible inhibition over the concentration range investigated.

*IC₅₀ values were calculated by fitting eq. 5 to experimental data using Enzfitter (see Materials and Methods). Each IC₅₀ value was derived from duplicate measurements at each of four inhibitor concentrations with cotinine as the substrate (see Materials and Methods). S.E. is the standard error of the parameter fit from Enzfitter.

The designation of primary, secondary, or tertiary amine or hydrazine refers to the N-containing functional group present in the side chain (aliphatic or alicyclic) attached to the mono-, bi-, or tetracyclic structure (Supplemental Fig. 1).
or alicyclic), although exceptions occur. All of the tricyclic and tetracyclic compounds, except olanzapine, overlaid well on the structure of amitriptyline (Fig. 4). Olanzapine is the only compound investigated in this work with a five-membered ring in the tricyclic scaffold, which results in a different geometry and poor overlay (Supplemental Fig. 2). The bis-ring structure of fluoxetine permits adoption of a conformation similar to that of amitriptyline, resulting in a reasonable overlay. Of the bicyclic compounds that exhibited significant inhibition, aripiprazole, duloxetine, and paroxetine aligned reasonably well with the structure of amitriptyline (Supplemental Fig. 2), whereas partial overlay was observed for sertraline (IC50 92.7 μM), presumably due to the shorter distance between the ring scaffold and side-chain amine group. Poor overlay of the SSRIs citalopram and fluvoxamine, including the side-chain amine of the latter (which aligns 3.3 Å from the side chain N of amitriptyline), provides an explanation for the weak inhibition observed with these compounds. Overlay on the structure of amitriptyline for the remaining compounds screened for inhibition (viz. haloperidol, venlafaxine, desvenlafaxine, and the MAOIs phenelzine, selegiline, and tranylcypromine), all of which lack a fused ring scaffold, was generally consistent with the observed potency of UGT2B10 inhibition (Supplemental Fig. 2).

Compared with other TCAs, the potent UGT2B10 inhibitors amitriptyline and doxepin share in common a side-chain tertiary amine functional group linked to the central cycloheptene ring by a double bond rather than to a potentially invertible N atom (Supplemental Fig. 1). The exocyclic double bond present in loratadine and desloratadine and the fused piperidine ring present in mianserin similarly confer structural rigidity. Near-identical geometries were observed for amitriptyline, doxepin, desloratadine, and loratadine, and, consequently, there was near-complete overlap of structural features (Fig. 5A). By contrast, conformational differences occur around the CH2-X moiety of the cycloheptene ring of other TCAs (e.g., imipramine), and the ring scaffold of tricyclic compounds with a six-membered central ring (e.g., chlorpromazine) is more planar (Fig. 5, B and C).

The Kinetics of Amitriptyline, Doxepin, and Mianserin Inhibition of Human Liver Microsomal UGT2B10 and In Vitro–In Vivo Extrapolation. Given the potent inhibition of UGT2B10 observed for amitriptyline, doxepin, and mianserin, kinetic studies were performed to determine the Ki values for inhibition of human liver microsomal cotinine N-glucuronidation. Incubations were supplemented with 1% w/v BSA (see above). Concentrations of amitriptyline,
doxepin, and mianserin were corrected for binding to HLM and BSA, and the inhibitor constants therefore represent $K_{i,u}$ values. The binding of each compound was independent of added concentration across the range 2–25 μM. Mean (±S.D.) values of $f_{u_{\text{max}}}$ for amitriptyline, doxepin, and mianserin were 0.32 ± 0.03, 0.42 ± 0.03, and 0.20 ± 0.01, respectively. As noted above, cotinine does not bind to either HLM or BSA. Amitriptyline, doxepin, and mianserin competitively inhibited human liver microsomal cotinine N-glucuronidation with mean $K_{i,u}$ (±S.D.) values of 0.61 ± 0.05, 0.95 ± 0.18, and 0.43 ± 0.01 μM (Fig. 6).

Using the plasma concentrations for amitriptyline, doxepin, and mianserin given above (for doses at the upper end of the usual recommended dosage ranges; viz. 150, 150, and 60 mg/d, respectively), respective $[I]/K_{i,u}$ ratios based on total drug concentration are 0.74, 0.92, and 0.88; corresponding values of $1 + [I]/K_{i,u}$ (see eq. 6 above) for amitriptyline, doxepin, and mianserin are 1.74, 1.92, and 1.88, respectively. When $[I]$ is taken as the unbound concentration of drug in plasma (i.e., the product of drug plasma concentration and $f_{u}$), $[I]/K_{i,u}$ values are <0.2.

**Discussion**

Initial studies confirmed that cotinine is a selective substrate for UGT2B10, and desloratadine and nicotine are relatively selective inhibitors of this enzyme. Cotinine N-glucuronidation by HLM followed Michaelis-Menten kinetics, consistent with the predominant involvement of a single UGT enzyme in this reaction. It has been reported previously that only UGT 1A4 and 2B10 glucuronidate cotinine (Kuehl and Murphy, 2003; Kaivosaari et al., 2007). This was confirmed in this work, although the cotinine N-glucuronidation activity of UGT1A4 was very low. To further elucidate the relative contributions of UGT2B10 and UGT1A4 to human liver microsomal cotinine N-glucuronidation, inhibition experiments were conducted with desloratadine and the UGT1A4 selective inhibitor hecogenin (Uchaipichat et al., 2006a). The separate and combined effects of desloratadine and hecogenin shown in Fig. 3 demonstrate that UGT2B10 is responsible for >90% of cotinine N-glucuronidation by HLM, making this compound a convenient, readily available UGT2B10 substrate probe. Moreover, compared with many other UGT enzyme-selective substrate probes, cotinine does not bind to BSA.
Consistent with the recent report of Kazmi et al. (2015b), desloratadine was shown to be a moderately selective inhibitor of UGT2B10 (Fig. 2B). The IC_{50} for UGT2B10 inhibition is approximately an order of magnitude lower than that for UGT2B4, the next most potently inhibited enzyme. UGT2B4 was not screened for inhibition in the study of Kazmi et al. (2015b). Thus, it may not be possible to differentiate relative contributions of UGT2B10 and UGT2B4 when desloratadine (10 μM; Kazmi et al., 2015b) is used for reaction phenotyping. Previous studies have reported that nicotine inhibits UGT2B10, but not UGT1A4 (Zhou et al., 2010). Similar specificity was observed in this study, although nicotine was observed to additionally inhibit UGT2B15, albeit less potently than UGT2B10.

Previously reported K_{m} and V_{max} values for cotinine N-glucuronidation by HLM range from 0.93 to 5.43 mM and 643 to 969 pmol/min/mg, respectively (Ghosheh and Hawes, 2002; Nakajima et al., 2002; Chen et al., 2007; Kaivosari et al., 2007), whereas K_{m} values of 0.47 and 1.0 mM have been reported for cotinine N-glucuronidation by recombinant UGT2B10 (Chen et al., 2007; Kaivosari et al., 2007). The mean K_{m} (2.78 mM) and V_{max} (297 pmol/mg.min) values for human liver microsomal cotinine N-glucuronidation determined in this study tended to be higher and lower, respectively, than previously reported values. The reasons for this are unclear, although 89-fold variability in the rates of nicotine N-glucuronidation has been observed in a panel of microsomes from 14 livers (Nakajima and Yokoi, 2005). The commercially sourced HLM employed in this study were a pool from 150 donors (equal numbers of males and females), whereas most reports have generally used microsomes from fewer donors (Ghosheh and Hawes, 2002; Nakajima et al., 2002; Kaivosari et al., 2007). Similarly, previous studies with UGT2B10 have used different expression systems to the Supersomes used in this work. Nevertheless, the differences in reported K_{m} values are surprising. Of note, we have found that the UGT2B10 activity of Supersomes remains stable for at least 6 months.

The addition of BSA (0.5–2% w/v) to incubations has been reported to decrease the K_{m} values (with occasional effects on V_{max}) for substrates of several hepatically expressed UGT enzymes, particularly UGT 1A9, 2B4, 2B7, and 2B15 (Rowland et al., 2007, 2008; Kilford et al., 2009; Manevski et al., 2011, 2013; Walsky et al., 2012). The albumin effect appears to arise from sequestration of inhibitory membrane fatty acids released during the course of an incubation. The effect of lower concentrations of BSA has been reported to be substrate dependent (Manevski et al., 2013), but this may arise from incomplete sequestration of inhibitory fatty acids at BSA concentrations <0.5% w/v. Addition of BSA (1% w/v) was found in this work to reduce the K_{m} for human liver microsomal nicotine N-glucuronidation by approximately 50%, with a small (11%) but statistically significant increase in V_{max}. Thus, subsequent inhibition kinetic studies included BSA to determine K_{i} values accurately. Furthermore, HLM were preferred to UGT2B10 in these studies due to the considerably lower cost of HLM compared with the recombinant enzyme.

UGT enzyme-selective inhibitors are a valuable experimental tool for the reaction phenotyping of human liver microsomal drug and chemical glucuronidation (Miners et al., 2010a). However, previous studies that have characterized UGT enzyme inhibition selectivity have generally excluded UGT2B10. Niflumic acid at a concentration of 2.5 μM is considered a highly selective inhibitor of UGT1A9 (Miners et al., 2011), whereas at 100 μM it additionally inhibits UGT1A1 and UGT2B15. The IC_{50} for niflumic acid inhibition of UGT2B10 observed in this study (168 μM) confirms the UGT1A9 inhibition selectivity of niflumic acid at a low concentration, but indicates that this compound will significantly inhibit UGT2B10 as well as UGT1A1 and UGT2B15 at a concentration of 100 μM. As noted above, hecogentin does not inhibit UGT2B10, consistent with the reported inhibition selectivity for UGT1A4 (Uchaipichat et al., 2006b). By contrast, fluconazole (2.5 mM), which is considered a selective inhibitor of UGT2B4 and UGT2B7, inhibited UGT2B10 to a similar extent to that reported for UGT2B4/7 (Uchaipichat et al., 2006a; Raungrut et al., 2010). The latter observation prompted us to investigate UGT2B10 inhibition by two additional azole antifungals: itraconazole and ketoconazole. Although the triazole itraconazole was without effect on UGT2B10, the imidazole ketoconazole was a relatively potent inhibitor of this enzyme (IC_{50} = 11.9 ± 1.7 μM). Similar to the inhibition selectivity of fluconazole, ketoconazole has previously been reported to be a relatively potent inhibitor of UGT2B4 (Raungrut et al., 2010) and an inhibitor of UGT2B7 (Takeda et al., 2006).

Previous studies have shown that the TCAs amitriptyline, clomipramine, imipramine, and trimipramine and the atypical antipsychotic olanzapine are substrates and/or inhibitors of UGT2B10 (Chen et al., 2007; Zhou et al., 2010; Guo et al., 2011; Kato et al., 2013). As noted in the Introduction, antidepressant and antipsychotic drugs typically contain an amine functional group. Thus, nine TCAs (plus the respective N-demethylated metabolites of desipramine and nortriptyline), five SSRIs, three SNRIs, three MAOIs, the tetracyclic antidepressants mianserin and mirtazapine, and six typical and four atypical antipsychotic drugs were screened for inhibition of UGT2B10. Although the majority of the compounds investigated inhibited UGT2B10 with IC_{50} values <100 μM, most potent inhibition was observed for the TCAs amitriptyline and doxepin and the tetracyclic mianserin. Desloratadine and loratadine were also potent inhibitors of UGT2B10. Structural interrogation of these data suggests that potent and moderate inhibition of UGT2B10 requires a hydrophobic domain (tetra-hri-bicyclic scaffold or an aromatic ring) and an amine (or hydrazine) functional group, which is most commonly located three bond lengths (C-C and/or C-N) from the hydrophobic domain. All but one of the potent inhibitors identified in this study, namely desloratadine, are tertiary amines. However, the presence of a tertiary amine is not an obligatory requirement for inhibition; moderate inhibition occurred with primary and secondary amines. Because the amines will be largely charged at physiologic pH, the data suggest that hydrophobic and charge interactions (e.g., with aspartic or glutamic acid) are involved in inhibitor binding.

The data also suggest that spatial features influence the potency of UGT2B10 inhibition. TCAs with a dihydrodibenzazepine moiety (e.g., clomipramine, desipramine, and imipramine) are inherently more flexible with more degrees of conformational freedom than dibenzocycloheptenes, such as amitriptyline and doxepin. It has been proposed that such conformational differences, particularly in the tricyclic ring scaffold, may be associated with differences in the receptor-binding selectivity and affinity of TCAs (Munro et al., 1987; Casarotto and Craik, 2001). As noted above and shown in Fig. 5, the relatively subtle conformational differences noted among amitriptyline, doxepin, desloratadine, and loratadine compared with other TCAs (e.g., imipramine) and tricyclic compounds with a six-membered central ring (e.g., antipsychotics such as chlorpromazine) may similarly account for differences in binding affinity to UGT2B10.

Given the potent inhibition (K_{i,a} < 1 μM) of human liver microsomal UGT2B10 by amitriptyline, doxepin, and mianserin, the potential of these drugs to inhibit UGT2B10-catalyzed drug glucuronidation was explored. Estimates of 1 + fII/K_{i,a} based on total drug concentration ranged from 1.74 to 1.92 for inhibitor doses at the upper end of the usual therapeutic dosage ranges, although doses double these may be used if required (Australian Medicines Handbook, 2015). However, no
clinically significant interactions were predicted when [I] was taken as the unbound drug concentration in plasma. As we have reported previously (Rowland et al., 2006; Raungrut et al., 2010; Pattanawongsa et al., 2015), prediction of DDI potential from in vitro data for drugs cleared by glucuronidation appears to be more accurate when [I] is taken as total drug concentration, despite the fact that unbound concentration in blood is expected to reflect the hepatocellular concentration. Based on the reported Kᵢ for desloratadine (~1 μM), Kazmi et al. (2015b) predicted a 2.2-fold increase in the AUC ratio for UGT2B10 substrates, which is similar to that proposed in this work for amitriptyline, doxepin, and mianserin. It is noteworthy that few compounds appear to be solely metabolized by UGT2B10, although the clearance of the experimental antipsychotic agent RO526397 appears to be mediated largely by UGT2B10 (Fowler et al., 2015).

The potent inhibition of UGT2B10 by several drugs observed in this study is consistent with previous reports from this laboratory, demonstrating that inhibition of other UGT enzymes (e.g., UGT 1A1, 1A9, 2B4, and 2B7) may potentially precipitate DDIs and drug-endobiotic interactions (Boyd et al., 2006; Uchai-pchat et al., 2006b; Miners et al., 2010b; Raungrut et al., 2010; Pattanawongsa et al., 2015). These observations reinforce the recent recommendations of Regulatory Agencies that new drugs should be evaluated for their potential to inhibit UGT enzymes.

**Authorship Contributions**

**Participated in research design:** Miners, Pattanawongsa, Nair, Rowland.

**Conducted experiments:** Pattanawongsa, Nair.

**Performed data analysis:** Pattanawongsa, Nair.

**Wrote or contributed to the writing of the manuscript:** Pattanawongsa, Nair.

**References**


**Address correspondence to:** Dr. John O. Miners, Department of Clinical Pharmacology, School of Medicine, Flinders University, GPO Box 2100, Adelaide, SA 5001, Australia. E-mail: john.miners@flinders.edu.au
Attarat Pattanawongsa, Pramod C. Nair, Andrew Rowland and John O. Miners. Human UDP-glucuronosyltransferase (UGT) 2B10: Validation of cotinine as a selective probe substrate, inhibition by UGT enzyme selective inhibitors and antidepressant and antipsychotic drugs, and structural determinants of enzyme inhibition. Drug Metabolism and Disposition.

**Supplemental data: Supplemental Tables 1 and 2, and Supplemental Figures 1 and 2.**

**Supplemental Table 1.** HPLC conditions for the quantification of amitriptyline, doxepin and mianserin in dialysates from equilibrium dialysis experiments.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Mobile phase composition</th>
<th>Detector wavelength (nm)</th>
<th>Retention time (min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amitriptyline</td>
<td>40%A : 60%C</td>
<td>240</td>
<td>6.0 (Amitriptyline)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>3.8 (Nortriptyline, IS)</td>
</tr>
<tr>
<td>Doxepin</td>
<td>48%A : 52%C</td>
<td>240</td>
<td>4.6 (Doxepin)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>6.7 (Imipramine, IS)</td>
</tr>
<tr>
<td>Mianserin</td>
<td>40%A : 60%C</td>
<td>240</td>
<td>4.4 (Mianserin)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>6.0 (Amitriptyline, IS)</td>
</tr>
</tbody>
</table>

*aColumn:* Nova-Pak® Waters, C18, 3.9 x 150 mm, 4 μm particle size.

*bColumn:* Zorbax Eclipse XBD-C8, 4.6 x 150 mm, 5 um particle size (Agilent).

**IS:** internal standard

**Mobile phase composition:**

A: 20 mM ammonium acetate (0.002% triethylamine) containing 10% acetonitrile.

B: 4 mM 1-octanesulfonic acid (adjusted to pH 2.7 with 11.6 M perchloric acid).

C: acetonitrile.
Supplemental Table 2. IC\textsubscript{50} values for nicotine and desloratadine inhibition of recombinant UGT enzymes.

<table>
<thead>
<tr>
<th>UGT enzyme</th>
<th>IC\textsubscript{50} ((\mu)M) ± SE of parameter fit</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Nicotine</td>
</tr>
<tr>
<td>UGT1A1</td>
<td>NI</td>
</tr>
<tr>
<td>UGT1A3</td>
<td>NI</td>
</tr>
<tr>
<td>UGT1A4</td>
<td>NI</td>
</tr>
<tr>
<td>UGT1A6</td>
<td>NI</td>
</tr>
<tr>
<td>UGT1A7</td>
<td>NI</td>
</tr>
<tr>
<td>UGT1A8</td>
<td>NI</td>
</tr>
<tr>
<td>UGT1A9</td>
<td>NI</td>
</tr>
<tr>
<td>UGT1A10</td>
<td>NI</td>
</tr>
<tr>
<td>UGT2B4</td>
<td>NI</td>
</tr>
<tr>
<td>UGT2B7</td>
<td>NI</td>
</tr>
<tr>
<td>UGT2B10</td>
<td>214 ± 2.86</td>
</tr>
<tr>
<td>UGT2B15</td>
<td>NI</td>
</tr>
<tr>
<td>UGT2B17</td>
<td>NI</td>
</tr>
</tbody>
</table>

NI – negligible inhibition over the concentration range investigated
Supplemental Figure 1. Chemical structures of compounds screened as inhibitors of UGT2B10.

**UGT Enzyme-Selective Inhibitors**

Desloratadine

Loratadine (desloratadine precursor)

Fluconazole

S-(-)-Nicotine

Niflumic acid

Phenylbutazone

Hecogenin

**Azoles**

Ketoconazole

Itraconazole
Antidepressants

TCAs

Primary amine

Desmethylnortriptyline  Didesmethylinipramine

Secondary amine

Desipramine  Norclomipramine  Nortriptyline  Protriptyline

Tertiary amine

Amitriptyline  Clomipramine  Doxepin
**Imipramine**

**Trimipramine**

**Tetracyclic-Tertiary amine**

**Mianserin**

**SSRIs**

**Primary amine**

**Fluvoxamine**
Secondary amine

Fluoxetine

Paroxetine

Sertraline

Tertiary amine

Citalopram

SNRIs
Secondary amine

Duloxetine
**Tertiary amine**

- Desvenlafaxine
- Venlafaxine

**SRM**

**Tertiary amine**

- Mirtazapine

**MAOIs**

**Primary amine**

- Tranylepromine
Tertiary amine

![R-(-)-Selegiline](image1)

Hydrazine

![Phenelzine](image2)

Antipsychotics

Typical antipsychotics

Tertiary amine

![Chlorpromazine](image3)

![Fluphenazine](image4)

![Haloperidol](image5)

![Loxapine](image6)
Atypical antipsychotics
Tertiary amine

Perphenazine
Thioridazine
Aripiprazole
Clozapine
Olanzapine
Quetiapine
**Supplementary Figure 2** Structural overlay of dataset molecules. The template molecule, amitriptyline used for the overlay is shown in ball and sticks (C atoms - green). The individual dataset molecules are shown in sticks (C atoms - orange). O, N S and Cl atoms are shown in red, blue, yellow, and green respectively.
Olanzapine $IC_{50} = 276 \mu M$

Mirtazapine $IC_{50} = 31 \mu M$

Haloperidol Inactive